Wright K, Collins D C, Preedy J R
Steroids. 1979 Oct;34(4):445-57. doi: 10.1016/0039-128x(79)90105-3.
The urinary excretion of estrone glucosiduronate, 17 beta-estradiol-17-glucosiduronate, and estriol-16 alpha-glucosiduronate in men and throughout the menstrual cycle in women was measured by specific radioimmunoassay. In 9 men the mean +/- SE excretion of these conjugates was 15.9 +/- 1.4, 2.7 +/- 0.3, and 3.2 +/- 0.2 microgram/24 h respectively. In 15 women studied in the midfollicular phase (day 8) of the menstrual cycle, the excretion was 19.4 +/- 1.7, 2.9 +/- 0.2, and 5.4 +/- 1.3 micrograms/24 h. Excretion of each conjugate was significantly (P less than 0.01) elevated in the midluteal phase (day 22) to 41.9 +/- 3.9, 6.3 +/- 0.8, and 12.2 +/- 1.5 micrograms/24 h respectively (n = 14). The mean excretion of estriol-16 alpha-glucosiduronate was greater than that of 17 beta-estradiol-17-glucosiduronate in the luteal phase (P less than 0.05) but not in the follicular phase or in men (P greater than 0.05). The excretion of each of these specific conjugates measured throughout the menstrual cycle in 7 women was characterized by a sharp midcycle peak and a lower, broader luteal phase peak. The ratios of estriol-16 alpha-glucosiduronate to 17 beta-estradiol-17-glucosiduronate, estrone glucosiduronate to 17 beta-estradiol-17-glucosiduronate, and estriol-16 alpha-glucosiduronate to estrone glucosiduronate throughout the menstrual cycle were analyzed. When the mean ratio during the follicular phase was set at 1, a significant increase (P less than 0.01) occurred in the mean luteal phase ratio in each case: 1.00 +/- 0.03 to 1.66 +/- 0.09, 1.00 +/- 0.04 to 1.30 +/- 0.04, and 1.00 +/- 0.03 to 1.24 +/- 0.04 (mean +/- SE) respectively. The marked alteration in the proportions of these urinary estrogen conjugates may be due to altered metabolism of 17 beta-estradiol, but it more likely reflects a change in the pattern of estrogen secretion or production between the two phases of the menstrual cycle.
采用特异性放射免疫分析法测定了男性以及女性整个月经周期中雌酮葡萄糖醛酸酯、17β-雌二醇-17-葡萄糖醛酸酯和雌三醇-16α-葡萄糖醛酸酯的尿排泄量。9名男性中,这些结合物的平均±标准误排泄量分别为15.9±1.4、2.7±0.3和3.2±0.2微克/24小时。在月经周期卵泡中期(第8天)研究的15名女性中,排泄量分别为19.4±1.7、2.9±0.2和5.4±1.3微克/24小时。在黄体中期(第22天),每种结合物的排泄量均显著升高(P<0.01),分别为41.9±3.9、6.3±0.8和12.2±1.5微克/24小时(n = 14)。在黄体期,雌三醇-16α-葡萄糖醛酸酯的平均排泄量大于17β-雌二醇-17-葡萄糖醛酸酯(P<0.05),但在卵泡期或男性中并非如此(P>0.05)。在7名女性整个月经周期中测量的这些特定结合物的排泄情况均表现为周期中期有一个急剧的峰值以及黄体期有一个较低、较宽的峰值。分析了整个月经周期中雌三醇-16α-葡萄糖醛酸酯与17β-雌二醇-17-葡萄糖醛酸酯、雌酮葡萄糖醛酸酯与17β-雌二醇-17-葡萄糖醛酸酯以及雌三醇-16α-葡萄糖醛酸酯与雌酮葡萄糖醛酸酯的比率。当将卵泡期的平均比率设定为1时,每种情况下黄体期的平均比率均出现显著增加(P<0.01):分别从1.00±0.03增加到1.66±0.09、从1.00±0.04增加到1.30±0.04以及从1.00±0.03增加到1.24±0.04(平均±标准误)。这些尿雌激素结合物比例的显著变化可能是由于17β-雌二醇代谢改变,但更可能反映了月经周期两个阶段之间雌激素分泌或产生模式的变化。